卵巢癌患者血清CD133和miR-145的表达与临床病理特征及预后的关系

Relationships between serum CD133 and miR-145 expressions in ovarian cancer patients and clinicopathological features and prognosis

目的研究卵巢癌患者血清CD133、miR-145的表达与临床病理特征及预后的关系。方法选择106例卵巢癌患者作为观察组,另选同期进行健康体检的女性志愿者106例为对照组,随访2年,对比两组血清CD133及miR-145的表达水平,分析卵巢癌患者的血清CD133及miR-145表达水平与病理体征及预后的关系。结果观察组术前血清CD133表达水平明显高于对照组,而miR-145表达水平明显低于对照组,两组比较,差异均有统计学意义(均P<0.05)。卵巢癌患者分化程度为中低分化、CA125≥200 U/ml、存在转移及FIGO分期为Ⅲ~Ⅳ的血清CD133表达水平明显更高,而miR-145表达水平明显更低(均P<0.05)。卵巢癌患者在术后7 d的血清CD133水平明显低于术前,miR-145水平明显高于术前(均P<0.05)。患者复发时的血清CD133水平明显高于术后7 d,miR-145水平明显低于术后7 d(P<0.05)。结论卵巢癌患者的血清CD133表达上调,而miR-145的表达下调,两者的表达与卵巢癌发生、发展及预后密切有关。临床上可考虑将血清CD133、miR-145作为生物标记物进行监测,从而更好地辅助临床诊治过程。

Objective To study the relationships between serum CD133 and miR-145 expressions in ovarian cancer patients and clinicopathological features and prognosis. Methods A total of 106 patients with ovarian cancer were selected as study group,and 106 healthy female volunteers were selected as control group during the same period,all the women were followed up for 2 years. The serum levels of CD133 and miR-145 were compared between the two groups,and the relationships with clinicopathological features and prognosis were analyzed. Results The expression level of CD133 in observation group was significantly higher than that in control group before treatment,while the expression level of miR-145 was significantly lower than that in control group,the differences were statistically significant（ P〈0. 05）. The expression levels of serum CD133 in patients with medium-poor differentiation degree of ovarian cancer,CA125≥200 U/ml,metastasis,and FIGO stage Ⅲ-Ⅳ were significantly higher,while the expression levels of miR-145 were significantly lower,the differences were statistically significant（ P〈0. 05）. The level of serum CD133 in patients with ovarian cancer on the seventh day after operation was significantly lower than that before operation,the level of serum miR-145 was significantly higher than that before operation,the differences were statistically significant（ P〈0. 05）. The level of serum CD133 in patients with recurrence was significantly higher than that in patients on the seventh day after operation,while the level of miR-145 was significantly lower than that in patients on the seventh day after operation,the differences were statistically significant（ P〈0. 05）. Conclusion The expression of CD133 in serum of patients with ovarian cancer is upregulated,while the expression level of miR-145 is downregulated. The expressions of CD133 and miR-145 are closely related to the occurrence,development,and prognosis of ovarian cancer. Serum CD133 and miR-145 can be considered as biomarkers for assist clinical diagnosis and treatment process.